AU663806B2 - New substituted azetidinones as anti-inflammatory and antidegenerative agents - Google Patents

New substituted azetidinones as anti-inflammatory and antidegenerative agents Download PDF

Info

Publication number
AU663806B2
AU663806B2 AU50283/93A AU5028393A AU663806B2 AU 663806 B2 AU663806 B2 AU 663806B2 AU 50283/93 A AU50283/93 A AU 50283/93A AU 5028393 A AU5028393 A AU 5028393A AU 663806 B2 AU663806 B2 AU 663806B2
Authority
AU
Australia
Prior art keywords
6alkyl
substituted
amino
hydrogen
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU50283/93A
Other languages
English (en)
Other versions
AU5028393A (en
Inventor
James B. Doherty
Conrad P. Dorn
Philippe L. Durette
Paul E. Finke
William K. Hagmann
Jeffrey J. Hale
Thomas J. Lanza
Malcolm Maccoss
Sander G. Mills
Soumya P Sahoo
Shrenik K. Shah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU5028393A publication Critical patent/AU5028393A/en
Application granted granted Critical
Publication of AU663806B2 publication Critical patent/AU663806B2/en
Assigned to MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME CORP. Request to Amend Deed and Register Assignors: MERCK & CO., INC.
Assigned to MERCK SHARP & DOHME CORP. reassignment MERCK SHARP & DOHME CORP. Request to Amend Deed and Register Assignors: MERCK SHARP & DOHME CORP.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU50283/93A 1992-10-27 1993-10-26 New substituted azetidinones as anti-inflammatory and antidegenerative agents Expired AU663806B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US96680092A 1992-10-27 1992-10-27
US99183892A 1992-12-17 1992-12-17
US966800 1992-12-17
US991838 1992-12-17

Publications (2)

Publication Number Publication Date
AU5028393A AU5028393A (en) 1994-05-12
AU663806B2 true AU663806B2 (en) 1995-10-19

Family

ID=27130493

Family Applications (1)

Application Number Title Priority Date Filing Date
AU50283/93A Expired AU663806B2 (en) 1992-10-27 1993-10-26 New substituted azetidinones as anti-inflammatory and antidegenerative agents

Country Status (29)

Country Link
EP (1) EP0595557B1 (enExample)
JP (1) JPH082868B2 (enExample)
KR (1) KR950704250A (enExample)
CN (1) CN1043884C (enExample)
AT (1) ATE270273T1 (enExample)
AU (1) AU663806B2 (enExample)
CA (1) CA2108584C (enExample)
CY (1) CY2529B1 (enExample)
CZ (1) CZ106895A3 (enExample)
DE (1) DE69333563T2 (enExample)
DK (1) DK0595557T3 (enExample)
DZ (1) DZ1724A1 (enExample)
ES (1) ES2224095T3 (enExample)
FI (1) FI951992A7 (enExample)
HR (1) HRP931309A2 (enExample)
HU (2) HUT72084A (enExample)
IL (1) IL107321A (enExample)
LV (1) LV13338B (enExample)
MX (1) MX9306666A (enExample)
MY (1) MY128261A (enExample)
NO (1) NO305697B1 (enExample)
NZ (1) NZ257755A (enExample)
PL (1) PL308545A1 (enExample)
PT (1) PT595557E (enExample)
RU (1) RU2148056C1 (enExample)
SI (1) SI9300566A (enExample)
SK (1) SK53795A3 (enExample)
TW (1) TW275621B (enExample)
WO (1) WO1994010142A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5420010A (en) * 1993-07-30 1995-05-30 Merck & Co., Inc. Assay for evaluating inhibition of polymorphonuclear leukocyte elastase by N-substituted azetidinones
AU5014496A (en) * 1995-03-23 1996-10-08 Japan Tobacco Inc. Diphenylmethyl-azetidinone compounds and elastase inhibitor
US5523233A (en) * 1995-05-03 1996-06-04 Merck & Co., Inc. Enzymatic hydrolysis of 3,3-diethyl-4-[(4-carboxy)phenoxy]-2-azetidinone esters
CA2234640A1 (en) * 1995-10-31 1997-05-09 Merck & Co., Inc. Process for preparing substituted azetidinones
US5808056A (en) * 1995-10-31 1998-09-15 Merck & Co., Inc. Process for preparing substituted azetidinones
JP2000502079A (ja) * 1995-12-08 2000-02-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アテローム性動脈硬化症の治療のための単環β―ラクタム誘導体
JP2000509049A (ja) * 1996-04-26 2000-07-18 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アテローム性動脈硬化症の治療用アゼチジノン誘導体
CN1202081C (zh) * 1998-06-25 2005-05-18 布里斯托尔-迈尔斯斯奎布公司 脒基和胍基β－丙内酰胺类胰蛋白酶抑制剂
AU4654199A (en) * 1998-07-23 2000-02-14 Shionogi & Co., Ltd. Monocyclic beta-lactam compounds and chymase inhibitors containing the same
RU2191570C1 (ru) * 2001-04-25 2002-10-27 Закрытое акционерное общество "ВЕРОФАРМ" Твердая лекарственная форма антимикробного средства
RU2207115C1 (ru) * 2001-12-27 2003-06-27 Закрытое акционерное общество "Брынцалов-А" Противомикробное средство тариферид
RU2217196C2 (ru) * 2002-02-28 2003-11-27 Небольсин Владимир Евгеньевич Способ индукции дифференцировки клеток
FR2861991B1 (fr) * 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
FR2937972B1 (fr) * 2008-11-04 2013-03-29 Galderma Res & Dev Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
KR101421785B1 (ko) * 2009-03-09 2014-07-22 다이호야쿠힌고교 가부시키가이샤 프로스타글란딘 ｄ 합성 효소를 저해하는 피페라진 화합물
FR2981933B1 (fr) * 2011-11-02 2013-11-15 Galderma Res & Dev Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3263089A (en) * 1988-04-11 1989-10-12 Merck & Co., Inc. New substituted azetidinones as anti-inflammatory and antidegenerative agents
AU8583391A (en) * 1988-04-11 1991-12-19 Merck & Co., Inc. New substituted azetidinones as anti-inflammatory and antidegenerative agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000332A1 (en) * 1991-06-25 1993-01-07 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3263089A (en) * 1988-04-11 1989-10-12 Merck & Co., Inc. New substituted azetidinones as anti-inflammatory and antidegenerative agents
AU8583391A (en) * 1988-04-11 1991-12-19 Merck & Co., Inc. New substituted azetidinones as anti-inflammatory and antidegenerative agents

Also Published As

Publication number Publication date
IL107321A (en) 1998-08-16
IL107321A0 (en) 1994-01-25
CN1090272A (zh) 1994-08-03
JPH082868B2 (ja) 1996-01-17
ES2224095T3 (es) 2005-03-01
CA2108584A1 (en) 1994-04-28
NZ257755A (en) 1998-03-25
SI9300566A (en) 1994-09-30
AU5028393A (en) 1994-05-12
RU2148056C1 (ru) 2000-04-27
LV13338B (en) 2006-01-20
EP0595557A1 (en) 1994-05-04
CY2529B1 (en) 2006-04-12
FI951992A0 (fi) 1995-04-26
SK53795A3 (en) 1995-09-13
WO1994010142A1 (en) 1994-05-11
NO951593D0 (no) 1995-04-26
DE69333563T2 (de) 2005-08-18
DK0595557T3 (da) 2004-10-25
NO305697B1 (no) 1999-07-12
ATE270273T1 (de) 2004-07-15
HRP931309A2 (en) 1997-02-28
CN1043884C (zh) 1999-06-30
EP0595557B1 (en) 2004-06-30
PT595557E (pt) 2004-10-29
MY128261A (en) 2007-01-31
RU95109936A (ru) 1997-01-10
TW275621B (enExample) 1996-05-11
CA2108584C (en) 1998-11-24
NO951593L (no) 1995-06-23
PL308545A1 (en) 1995-08-21
DZ1724A1 (fr) 2002-02-17
DE69333563D1 (de) 2004-08-05
JPH06263723A (ja) 1994-09-20
CZ106895A3 (en) 1996-03-13
MX9306666A (es) 1994-04-29
HU9501184D0 (en) 1995-06-28
FI951992A7 (fi) 1995-04-26
HUT72084A (en) 1996-03-28
KR950704250A (ko) 1995-11-17
HU211619A9 (en) 1995-12-28

Similar Documents

Publication Publication Date Title
AU663806B2 (en) New substituted azetidinones as anti-inflammatory and antidegenerative agents
DE69727308T2 (de) HETEROCYCLENDERIVATE DIE FAKTOR Xa HEMMEN
WO1999028297A1 (de) Substituierte indole mit thrombin-hemmender wirkung
DE69921994T2 (de) Heterozyklische verbindungen mit faktor xa hemmender wirkung
EP0482208A4 (en) Pyridazinone derivative
DE19851421A1 (de) Neue Pyrimidine, deren Herstellung und Verwendung
AU4437896A (en) Piperidine derivatives having tachykinin antagonist activity
EP0481342A1 (en) Quinazoline derivatives and their preparation
US5348953A (en) Substituted azetidinones as anti-inflammatory and antidegenerative agents
AU7581996A (en) 3-(4-subst.-piperidinyl-1)-1-(3,4-dichlorophenyl)propyl carbamates and ureas and derivatives as novel neurokinin antagonists
US5952321A (en) Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5747485A (en) Substituted azetidiones as anti-inflammatory and antidegenerative agents
DE69923444T2 (de) Heterozyklische verbindungen mit faktor xa hemmender wirkung
US5116842A (en) Chemical compounds
DE4243858A1 (de) Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
IL117093A0 (en) Heterocyclic derivatives
US5591737A (en) Substituted azetidinones as anti-inflammatory and antidegenerative agents
DE69928257T2 (de) Amidino- und guanidino-azetidinon tryptase-inhibitoren
SK12842000A3 (sk) Deriváty streptogramínov, spôsob ich prípravy a kompozície s ich obsahom
AU686780B2 (en) Composition for the treatment of lung disease
HK1008333A (en) New substituted azetidinones as anti-inflammatory and antidegenerative agents
DE4424828A1 (de) Neue substituierte Arylsulfonamide, ihre Herstellung und ihre Verwendung als Arzneimittel